On March 14th, the Social Security Bureau of Ningxia Hui Autonomous Region issued the Procedures for Handling Serious Illness Insurance Business for Urban and Rural Residents in Ningxia Hui Autonomous Region (Ning Social Security Fa [216] No.7) and the List of Serious Illness Insurance Drugs for Urban and Rural Residents in Ningxia Hui Autonomous Region (Ning Ren She Fa [216] No.23), which included velcade in the list of serious illness insurance drugs for urban and rural residents. This is the second time that velcade has been included in the scope of medical insurance after the Hunan Provincial Department of Human Resources and Social Security and the Health Planning Commission issued a document in January this year to include bortezomib (velcade) in the scope of major illness insurance. So far, across the country, Inner Mongolia, Qingdao, Shenzhen and other provinces, autonomous regions and municipalities have launched this initiative to benefit the people.
On March 8, Li Bin, director of the National Health Planning Commission, answered a reporter's question during the two sessions. In view of the current situation that some patented drugs and imported drugs are too expensive for ordinary people to use, he said that the Health Planning Commission has begun to take measures to start national negotiations with five drugs as pilots, and the decline of these drugs may be more than 5%. Among these five drugs, lenalidomide ranks first. At present, the domestic sales price of lenalidomide is 59, yuan (25mg× 21 capsules/box) and 46, yuan (1mg× 21 capsules/box), and the average annual drug treatment cost of patients is 6,-7, yuan. After the price reduction, these drugs may gradually enter the list of major illness insurance drugs in various places.
Attached to the "Procedures for Handling Serious Illness Insurance for Urban and Rural Residents in Ningxia Hui Autonomous Region" (Ning She Bao Fa [216] No.7) chain
Extended reading: How to buy insurance, which is good, and teach you how to avoid these "pits" of insurance.